A novel solution will offer better absorption of the drug resulting in quick relief and faster recovery to patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders
• Lincoln Pharmaceuticals Ltd becomes the first healthcare company to launch Diclofenac Rectal Spray formulation; Company will soon apply for a Global Patent
• Company will launch the product in the Indian market by Jan 2020; Looks to export in African, Latin America and Southeast Asia markets and expand to other markets
• Studies of clinical trials suggest Diclofenac rectal spray is highly effective in patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders associated with arthritis, acute pain
• Diclofenac Rectal Suppository market is Rs. 20 crore in India and growing at 16% per annum.
October 22, 2019: Ahmedabad based leading healthcare company, Lincoln Pharmaceuticals Ltd is awarded a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray). The patent has been awarded by the Government of India for “A Novel Liquid Rectal Spray Dosage Form Containing Diclofenac and Its Pharmaceutically Active Salts”, patent number - IN320894. This patent is valid for 20 years. The company has necessary approvals from Drug Controller General of India (DCGI) and planning to launch it in the Indian market by January 2020. The Company is also planning to apply for a Global Patent for this novel solution.
Lincoln Pharma's Liquid rectal spray dosage offers faster and better absorption of the drug resulting in quick relief and speedy recovery to patients compared to the existing therapeutic options. Clinical Trials conducted suggest that Diclofenac Rectal Spray is highly effective in patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders such as muscular pain, pain associated with arthritis, acute pain in renal colic and mild body ache.
Speaking on this development, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd, said, "Globally, No liquid formulation of diclofenac for rectal administration is available. Lincoln Pharma will be the first company to introduce this novel solution aimed at better patient compliance, rapid drug release and greater bioavailability. We have developed this formulation with Diclofenac Sodium BP 25% W/V, each squirt delivers Diclofenac Sodium 50 mg, Non-steroidal Anti-inflammatory Agent (NSAIDs). Due to this innovation, now patients can get far better results by using Diclofenac Rectal Spray as compared to the existing Diclofenac Suppository available in the market. We are planning to apply for a Global patent for this solution."
Diclofenac Rectal Suppository market is Rs. 20 crore in India and growing at 16% per annum. The company see huge export potential for this product and will start product registration in markets including African continents, Latin America and Southeast Asian markets and gradually expand to other markets.
Lincoln Pharmaceuticals Ltd has a strong R&D team including 30 plus scientists. It has filled 20 plus patent applications and is awarded five patents. The company has developed 300 plus formulations in 15 plus therapeutic areas including anti-infectives, respiratory system, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.
Company :-Lincoln Pharma
User :- Gopal Modi